Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by drd8on Oct 28, 2022 3:03pm
396 Views
Post# 35056618

has no one seen this

has no one seen this

AYACORP B.S.C. (c) ("SAYACORP"), headquartered in the Kingdom of Bahrain, assisted by SAYACORP CAPITAL LTD ("SAYACORP CAPITAL"), its wholly owned subsidiary based in the Dubai International Financial Centre (DIFC), has successfully led and completed an oversubscribed funding round. SAYACORP's shareholders are mainly Sovereign Wealth Funds, leading institutions and family offices from the Gulf Cooperation Council (GCC) and the Middle East and North Africa (MENA) region, and its portfolio includes investments in food manufacturing, healthcare, pharmaceuticals, energy, commercial property and aviation industries.

SAYACORP CAPITAL's CEO, Mohamed Idriss commented "This is a very exciting moment for SAYACORP, as it demonstrates the group's vision of backing technology companies in massive growing markets at a stage when the most value can be realized. Cognetivity has an incredible technology platform that will have a great positive impact both commercially and socially, and as demonstrated by their early commercial success including in the Middle East, is truly globally scalable." He added "By directly backing and supporting the ongoing growth of companies like Cognetivity, the group aims to be proactive with its investments; both in delivering significant returns and making a positive impact on people's lives. This transaction is in line with the group's investment strategy, to work with undervalued firms which demonstrate potential and help them to become successful."

<< Previous
Bullboard Posts
Next >>